Search Technologies
Displaying 11 - 20 of 26 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Anthrax toxin protective antigen proteins engineered to target membrane-anchored serine proteases overexpressed on tumor cells
Published Friday, January 26, 2018Bacillus anthracis is the bacterium that produces the anthrax toxin, which consists of the three distinct proteins protective antigen (PrAg), lethal factor (LF), and edema factor (EF). In order for the toxin to be activated, the PrAg moiety of the toxin must bind to cell-surface proteins and become proteolytically cleaved by the proprotein...
Investigator(s): Toni Antalis, Erik Martin
Categories: Therapeutics, Biologics
Keyword(s): oncology, protein therapy, anthraz, ZMT
Docket: TA-2016-015
-
Histatin-5-Based Antifungal Peptides for Oral Topical Applications
Published Tuesday, October 31, 2017Candida albicans is a fungus colonizing human mucosal surface. It commonly causes recurrent infections which can become life-threatening in immunosuppressed and immunocompromised patients. Histatin-5 (Hst-5) is a cationic antimicrobial peptide found in saliva with antifungal activity against C. albicans, related fungal...
Investigator(s): Mary Ann Jabra-Rizk, Amy Karlsson, Timothy F. Meiller
Categories: Therapeutics, Biologics
Keyword(s): Candida, fungus, Biofilm, antimicrobial
Docket: MR-2016-100
-
Use of ELA peptide for treatment of cardiovascular disease and for improving fluid homeostasis
Published Tuesday, October 20, 2015Cardiovascular disease (CVD) continues to be one of America’s most serious and costly health issues. Though many therapeutic options exist to treat CVD, the majority of treatments address the symptoms of the disease and not the disease itself. This technology is a new class of therapeutic fusion proteins using the hormone Elabela (ELA) to...
Investigator(s): Da-Wei Gong (Lead PI)
Categories: Therapeutics, Biologics, Methods of Treatment
Keyword(s): MI, peptide, heart failure, myocardial infarction, cardiovascular, obesity, ELA, apelin
Docket: DG-2014-128
-
Use of Micro-RNA Mimics as Therapeutic Agents for Inhibition of Neuronal Apoptosis Following Traumatic Brain Injury.
Published Tuesday, August 25, 2015Reduced blood flow to the brain due to thrombosis, embolism, cardiac arrest, or injury, can result in focal or global cerebral ischemia. Ischemia leads to alterations in brain metabolism, reduction in metabolic rates, and subsequent neuronal death. Ischemia can have irreversible sequela. Post-injury treatment to curtail cell death due to acute...
Investigator(s): Alan Faden, Bogdan Stoica, Boris Sabirzhanov
Categories: Therapeutics, Small molecules, Biologics
Keyword(s): Traumatic Brain Injury, micro RNA, miRNA mimics, ischemia
Docket: AF-2014-011
-
Protein-Coated Microspheres for the Treatment of Inflammatory Bowel Conditions
Published Tuesday, June 30, 2015Chronic inflammation of the bowel is estimated to affect over 20% of Americans with only a small subset of individuals being clinically diagnosed with the autoimmune diseases Crohn’s and ulcerative colitis (UC). Researchers at the University of Maryland, Baltimore have developed a targeted therapeutic approach that may be...
Investigator(s): Erik P.H. de Leeuw; Wuyuan Lu
Categories: Therapeutics, Biologics, Methods of Treatment
Keyword(s): microsphere, defensin, inflammatory bowel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, surface-like protein
Docket: ED-2010-131
-
Tight junction permeation enhancer peptides
Published Monday, March 23, 2015Human zonulin or pre-haptoglobin 2 (HP2) is known to reversibly regulate intestinal permeability by modulating intercellular tight junctions. Itactivates protease-activated receptor (PAR) 2, and induces signaling...
Investigator(s): Alessio Fasano, Stefanie N. Vogel
Categories: Research Tools, Antibodies, & Reagents, Therapeutics, Small molecules, Biologics, Methods of Treatment
Keyword(s): peptides, zot, zonulin, crohns asthma, glioma, celiac disease, type I diabetes, tight junction
Docket: AF-2004-004
-
Use of Omentin for Treatment and Prediction of Disease
Published Wednesday, January 28, 2015Obesity, especially accumulation of abdominal fat, is a risk factor for the development of type 2 diabetes and cardiovascular disease. More than one-third of US adults are considered to be obese. Omentin is an adipokine expressed and secreted from abdominal but not subcutaneous...
Investigator(s): Da-Wei Gong, Alan Shuldiner, John McLenithan, Rongze Yang
Categories: Research Tools, Antibodies, & Reagents, Diagnostics, Therapeutics, Biologics, Biomaterials
Keyword(s): omentin, diabetes, obesity, cardiovascular
Docket: DG-2002-013, DG-2007-087, DG-2009-093
-
Broad spectrum antibacterial therapeutic peptides of probiotic origin
Published Thursday, May 29, 2014Bacterial diarrhea still remains the second leading cause of deaths globally, accounting for one fifth of all deaths among children under five. Small bioactive peptides with both Gram-positive and Gram-negative bactericidal activity have been isolated from Lactobacillus GG. These peptides...
Investigator(s): Alessio Fasano, Ruiliang Lu
Categories: Therapeutics, Biologics
Keyword(s): diarrhea, pathogenic bacteria, peptides, probiotic, Lactobacillus, broad spectrum, biologics
Docket: SF-2006-008
-
Prostaglandin D2 metabolites for treatment of optic nerve diseases
Published Wednesday, May 28, 2014Blockage of blood supply to part or all of the optic nerve within the eye can lead to death or dysfunction of optic nerve cells and is termed non-arteritic ischemic optic neuropathy (NAION). NAION is the most common cause of sudden optic nerve related vision loss and affects about 10,000 Americans every year. Currently there is no effective,...
Investigator(s): Steven Lance Bernstein
Categories: Therapeutics, Biologics
Keyword(s): eye, Ophthalmology, stroke, ischemia, neuroprotection, orphan
Docket: SB-2008-026
-
PSA peptides for prostate cancer immunotherapy
Published Wednesday, May 28, 2014Prostate Specific Antigen (PSA) is a protein produced solely by prostate tissue, including tumors, and is considered a promising target for development of a prostate cancer vaccine. In fact, other groups are currently developing candidate vaccines focused on Class I-restricted CD8+ T-cell immunity, but the ultimate success of those efforts is...
Investigator(s): Richard Alexander, Elena Klyushnenkova, Arthur Vandenbark, Jason Link
Categories: Therapeutics, Biologics, Vaccines
Keyword(s): prostate cancer
Docket: RA-2004-035